Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive andirreversible worsening of cognitive functions, inability to perform everyday activities, and mooddisorders. Currently, AD is considered the leading cause of dementia and hospitalization of olderadults in nursing homes. In the United States, 5.8 million people has been calculated to suffer fromAD in 2019, 81% being 75 years or older; the percentage of individuals with AD increases with age,from 3% of people aged 65–74 to 32% of people aged 85 and older. Women are more affected by ADthan men (M/F 2/1) probably because of their longer lifespan. Finally, African Americans andHispanics are about twice likely to develop AD as older Whites (Alzheimer’s Association, 2019). Thelack of any updated epidemiologic survey about AD in Europe is quite disappointing; the mostaccurate analysis dates back 2017 and reveals an estimated prevalence at 5.05% (men 3.31% andwomen 7.13%) increasing with age (Niu et al., 2017). In Europe, about 3 million people wasestimated to suffer from AD (Mayer et al., 2018)

Editorial: Alzheimer’s disease: original mechanisms and translational impact / Mancuso, C.; Gaetani, S.. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - 11:(2020). [10.3389/fphar.2020.00157]

Editorial: Alzheimer’s disease: original mechanisms and translational impact

Gaetani S.
2020

Abstract

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive andirreversible worsening of cognitive functions, inability to perform everyday activities, and mooddisorders. Currently, AD is considered the leading cause of dementia and hospitalization of olderadults in nursing homes. In the United States, 5.8 million people has been calculated to suffer fromAD in 2019, 81% being 75 years or older; the percentage of individuals with AD increases with age,from 3% of people aged 65–74 to 32% of people aged 85 and older. Women are more affected by ADthan men (M/F 2/1) probably because of their longer lifespan. Finally, African Americans andHispanics are about twice likely to develop AD as older Whites (Alzheimer’s Association, 2019). Thelack of any updated epidemiologic survey about AD in Europe is quite disappointing; the mostaccurate analysis dates back 2017 and reveals an estimated prevalence at 5.05% (men 3.31% andwomen 7.13%) increasing with age (Niu et al., 2017). In Europe, about 3 million people wasestimated to suffer from AD (Mayer et al., 2018)
2020
Alzheimer’s disease; drug research and development; neurodegeneration; preclinical studies; synaptic plasticity
01 Pubblicazione su rivista::01m Editorial/Introduzione in rivista
Editorial: Alzheimer’s disease: original mechanisms and translational impact / Mancuso, C.; Gaetani, S.. - In: FRONTIERS IN PHARMACOLOGY. - ISSN 1663-9812. - 11:(2020). [10.3389/fphar.2020.00157]
File allegati a questo prodotto
File Dimensione Formato  
Mancuso_Editorial_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 223.31 kB
Formato Adobe PDF
223.31 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1402429
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact